Genetic Polymorphism of NAT2 Metabolizing Enzymes on Phenytoin Pharmacokinetics in Indian Epileptic Patients Developing Toxicity

CNS Neuroscience and Therapeutics

Volumn 18, Issue 4, 2012, Pages 350-358

  Murali, M ^a   Manjari, T ^a   Madhuri, B ^a   Raghavan, S ^b   Jain, D C ^b   Vivekanandhan, S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b SAFDARJUNG HOSPITAL   (India)

Author keywords

Epilepsy; NAT2 enzymes; Pharmacokinetics; Phenytoin

Indexed keywords

DRUG METABOLIZING ENZYME; DRUG METABOLIZING ENZYME NAT2; PHENYTOIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GRAND MAL SEIZURE; HUMAN; INDIAN; MALE; MAXIMUM PLASMA CONCENTRATION; SIMPLE PARTIAL SEIZURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; EPILEPSY; FEMALE; GENE FREQUENCY; HUMANS; INDIA; MALE; PHENYTOIN; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84859507171     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2011.00291.x     Document Type: Article

References (34)

1. Shorvon SD. Handbook of the treatment of epilepsy. Oxford: Blackwell Science, 2000;252 pp. ISBN 0-632-04849-2.
2. Shridharan R, Murthy BN. Prevalence and pattern of epilepsy in India. Epilepsia 1999;40:631-636.
3. Najm IM, Moddel G, Janigro D. Mechanisms of epileptogenesis and experimental models of seizures. In: Wyllie E, editor. The treatment of epilepsy, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2006;91-102.
4. Odani A, Hashimoto Y, Otsiki Y, Uuai Y, Hattori H, Furusho K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997;62:287-292.
5. Evans DAP. N-Acetyltransferase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992;95-178.
6. Harmer D, Evans DAP, Eze LC, Jolly M, Whibley EJ. The relationship between the acetylation and the sparteine hydroxylation polymorphisms. J Med Genet 1986;23:155-156.
7. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DAP, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
8. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: Isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990;9:193-203.
9. Grant DM, Blum M, Demierre A, Meyer UA. Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res 1989;17:3978.
10. Hickman D, Risch A, Buckle V, Spurr NK, Jeremiah SJ, McCarthy A, Sim E. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994;297:441-445.
11. NAT2 Nomenclature. Available from:
12. Comey CT, Koons BW, Presley KW, Smerick JB, Sobieralski CA, Stanley DM. DNA extraction strategies for amplified fragment length polymorphism analysis. J Forensic Sci 1994;39:1254-1269.
13. Smith CAD, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 1997;34:758-760.
14. Bhatti MM, Hanson GD, Schultz L. Simultaneous determination of phenytoin, carbamazepine, and 10, 11-carbamazepine epoxide in human plasma by high-performance liquid chromatography with ultraviolet detection. J Pharmaceu Biomed Anal 1998;16:1233-1240.
15. Browne TR. Pharmacokinetics of antiepileptic drugs. Neurology 1998;51:2-7.
16. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269-296.
17. Eadie MJ. Formation of active metabolites of anticonvulsant drugs: A review of their pharmacokinetic and therapeutic significance. Clin Pharmacokinet 1991;21:27-41.
18. Aziz H, Guvener A, Akhtar SW, Hasan KZ. Comparative epidemiology of epilepsy in Pakistan and Turkey: Population-based studies of the major using identical protocols. Epilepsia 1997;38:716-722.
19. Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: Inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol 2001;57:31-36.
20. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major maetabolite. Drug Metab Dispos 1996;24:1401-1403.
21. Grant DM, Goodfellow GH, Sugamori K, Durette K. Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology 2000;61:204-211
22. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988;948:37-66.
23. Evans DAP. N-Acetyltransferase. Pharmacol Ther 1989;42:157-234.
24. Grant, DM, Hughes NC, Janezic SA, et al. Human acetyltransferase polymorphisms. Mutat Res 1997;376:61-70.
25. Rothman N, Hayes RB, Bi W, et al. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993;3:250-255.
26. Mrozikiewicz PM, Cascorbi I, Brockmoller J, Roots I. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther 1996;59:376-382.
27. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity. Am J Hum Genet 1995;57:581-592.
28. Bell DA, Taylor JA, Butler MA et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African- Americans. Carcinogenesis 1993;14:1689-1692
29. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow-acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994;4:125-134.
30. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbard LE, Gilman AG, editors. Goodman and Gilman's: The pharmacological basis of therapeutics. New York: McGraw-Hill, 2001;528-530.
31. Bochner F, Hooper WD, Tryer J, Eadie MJ. Effect of dosage increments on blood phenytoin concentrations. J Neurol Neurosurg Psychiatr 1972;35:873-876.
32. Richens A. A study of the pharmacokinetics of phenytoin in epileptic patients and the development of a nomogram for making dose increments. Epilepsia 1975;16:627-646.
33. Arnold K, Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol Ther 1970;11:121-134.
34. Kerb R, Aynacioglu AS, Brockmoller J, et al. The predictive value of MDR1, CYP2C9 and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001;1:204-210.